Establishing a Reference Framework for Outcomes After Machine-Preserved Liver Transplantation in Europe (REFRAME-MP)
Establishing a Reference Framework for Outcomes After Machine-Preserved Liver Transplantation in Europe (REFRAME-MP)
Machine perfusion (MP) has become routine clinical practice in liver transplantation. However, as the field has matured, direct randomized comparisons between distinct MP modalities have become increasingly impractical, given that donor and graft characteristics often predetermine the optimal preservation strategy. Consequently, many studies continue to reference historical benchmark cohorts from the pre-perfusion era, or use risk scores developed before routine utilization of MP. These cohorts, while once valuable, fail to account for the paradigm shift that MP has introduced. Likewise, commonly used donor- and recipient-based risk scores were developed prior to the adoption of MP. While these scores aim to assess survival or morbidity after transplantation, none of them guide decisions about MP use or the most suitable perfusion protocol. As MP technologies continue to evolve there is a critical need for an updated reference framework that accurately reflects current clinical practice and captures the best achievable outcomes across all MP modalities.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
- Device: Endischemic hypothermic oxygenated machine perfusion (any device)
- Device: Endischemic (back-to-base) normothermic machine perfusion (any device)
- Device: Continuous (device-to-donor) normothermic machine perfusion (any device)
- Device: Endischemic HOPE-COR-NMP (any device)
- Device: Endischemic HOPE-NMP (any device)
- Device: Normothermic regional perfusion (any device)
- Other: Static cold storage
Detailed Description
The aim of this study is to establish a reference framework for liver transplantation outcomes in the era of routine clinical machine perfusion. In addition, based on the collected real-world observational data, a target trial emulation approach will be applied.
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Sabrina Stimmeder, MD
- Phone Number: +31503612896
- Email: s.stimmeder@umcg.nl
Study Locations
-
-
-
Innsbruck, Austria
- Recruiting
- Medical University of Innsbruck
-
Contact:
- Stefan Schneeberger, MD, PhD
- Phone Number: +4351290030
- Email: stefan.schneeberger@i-med.ac.at
-
Principal Investigator:
- Stefan Schneeberger, MD, PhD
-
Vienna, Austria
- Not yet recruiting
- Medical University of Vienna
-
Contact:
- Deniz Uluk, MD
- Phone Number: +431401600
- Email: deniz.uluk@meduniwien.ac.at
-
Principal Investigator:
- Deniz Uluk, MD
-
-
-
-
-
Brussels, Belgium
- Not yet recruiting
- Cliniques universitaires Saint-Luc
-
Contact:
- Eliano Bonaccorsi-Riani, MD, PhD
- Phone Number: +3227641111
- Email: Eliano.Bonaccorsi@saintluc.uclouvain.be
-
Principal Investigator:
- Eliano Bonaccorsi-Riani, MD, PhD
-
Ghent, Belgium
- Not yet recruiting
- UZ Ghent
-
Contact:
- Hasan Eker, MD, PhD
- Phone Number: +3293322111
- Email: hasan.eker@uzgent.be
-
Principal Investigator:
- Hasan Eker, MD, PhD
-
Leuven, Belgium
- Not yet recruiting
- University Hospitals Leuven
-
Contact:
- Diethard Monbaliu, MD, PhD
- Phone Number: +3216332211
- Email: diethard.monbaliu@uzleuven.be
-
Principal Investigator:
- Diethard Monbaliu, MD, PhD
-
-
-
-
-
Prague, Czechia
- Not yet recruiting
- Institute of Clinical and Experimental Medicine
-
Contact:
- Jiri Froněk, MD, PhD
- Phone Number: +420236051111
- Email: jiri.fronek@ikem.cz
-
Principal Investigator:
- Jiri Froněk, MD, PhD
-
-
-
-
-
Clermont-Ferrand, France
- Not yet recruiting
- Clermont-Ferrand University Hospital
-
Contact:
- Johan Gagnière, MD, PhD
- Phone Number: +33473750750
- Email: jgagniere@chu-clermontferrand.fr
-
Principal Investigator:
- Johan Gagnière, MD, PhD
-
Clichy, France
- Not yet recruiting
- Beaujon Hospital
-
Contact:
- Mickaël Lesurtel, MD, PhD
- Phone Number: +33140875000
- Email: mickael.lesurtel@aphp.fr
-
Principal Investigator:
- Mickaël Lesurtel, MD, PhD
-
Lyon, France
- Not yet recruiting
- Hôpital de la Croix-Rousse
-
Contact:
- Xavier Muller, MD, PhD
- Phone Number: +33472118088
- Email: xavier.muller@chu-lyon.fr
-
Principal Investigator:
- Xavier Muller, MD, PhD
-
Nice, France
- Not yet recruiting
- Nice University Hospital
-
Contact:
- Michel Rayar, MD, PhD
- Phone Number: +33492037777
- Email: rayar.m@chu-nice.fr
-
Principal Investigator:
- Michel Rayar, MD, PhD
-
Strasbourg, France
- Not yet recruiting
- Hautepierre Hospital
-
Contact:
- Pietro Francesco Addeo, MD, PhD
- Phone Number: +33388116768
- Email: pietrofrancesco.addeo@chru-strasbourg.fr
-
Principal Investigator:
- Pietro Francesco Addeo, MD, PhD
-
Villejuif, France
- Not yet recruiting
- Hôpital Paul-Brousse Ap-Hp
-
Contact:
- Marc-Antoine Allard, MD, PhD
- Phone Number: +33145593000
- Email: marcantoine.allard@aphp.fr
-
Principal Investigator:
- Marc-Antoine Allard, MD, PhD
-
-
-
-
-
Aachen, Germany
- Not yet recruiting
- Aachen University Hospital
-
Contact:
- Florian Vondran, MD, PhD
- Phone Number: +49241800
- Email: fvondran@ukaachen.de
-
Principal Investigator:
- Florian Vondran, MD, PhD
-
Berlin, Germany
- Not yet recruiting
- Charité - Universitätsmedizin Berlin
-
Contact:
- Nathanael Raschzok, MD, PhD
- Phone Number: +493045050
- Email: nathanael.raschzok@charite.de
-
Principal Investigator:
- Nathanael Raschzok, MD, PhD
-
Bonn, Germany
- Not yet recruiting
- University Hospital Bonn
-
Contact:
- Christiane Pillny, MD
- Phone Number: +492282870
- Email: christiane.pillny@ukbonn.de
-
Principal Investigator:
- Christiane Pillny, MD
-
Principal Investigator:
- Steffen Manekeller, MD, PhD
-
Essen, Germany
- Recruiting
- University Hospital Essen
-
Principal Investigator:
- Ulf Neumann, MD, PhD
-
Contact:
- Zoltan Czigany, MD, PhD
- Phone Number: +492017230
- Email: zoltan.czigany@uk-essen.de
-
Principal Investigator:
- Zoltan Czigany, MD, PhD
-
Hanover, Germany
- Not yet recruiting
- Hannover Medical School
-
Contact:
- Moritz Schmelzle, MD, PhD
- Phone Number: +495115320
- Email: schmelzle.moritz@mh-hannover.de
-
Principal Investigator:
- Moritz Schmelzle, MD, PhD
-
Heidelberg, Germany
- Not yet recruiting
- University Hospital Heidelberg
-
Contact:
- Peri Husen, MD, PhD
- Phone Number: +496221560
- Email: peri.husen@med.uni-heidelberg.de
-
Principal Investigator:
- Peri Husen, MD, PhD
-
Principal Investigator:
- Christoph Mickalski, MD, PhD
-
Magdeburg, Germany
- Not yet recruiting
- University Hospital Magdeburg
-
Contact:
- Roland Croner, MD, PhD
- Phone Number: +493917601
- Email: roland.croner@med.ovgu.de
-
Principal Investigator:
- Roland Croner, MD, PhD
-
München, Germany
- Not yet recruiting
- Ludwig Maximilian University of Munich
-
Contact:
- Dionysios Koliogiannis, MD
- Phone Number: +498921800
- Email: Dionysios.Koliogiannis@med.uni-muenchen.de
-
Principal Investigator:
- Dionysios Koliogiannis, MD
-
Münster, Germany
- Not yet recruiting
- University Hospital Muenster
-
Contact:
- Philipp Houben, MD, PhD
- Phone Number: +492518355555
- Email: philipp.houben@ukmuenster.de
-
Principal Investigator:
- Philipp Houben, MD, PhD
-
Principal Investigator:
- Andreas Pascher, MD, PhD
-
Tübingen, Germany
- Not yet recruiting
- Tübingen University Hospital
-
Contact:
- Silvio Nadalin, MD, PhD
- Phone Number: +497071290
- Email: silvio.nadalin@med.uni-tuebingen.de
-
Principal Investigator:
- Silvio Nadalin, MD, PhD
-
-
-
-
-
Bari, Italy
- Not yet recruiting
- A.O.U Consorziale Policlinico di Bari
-
Contact:
- Francesco Tandoi, MD, PhD
- Phone Number: +390805591111
- Email: francesco.tandoi@uniba.it
-
Principal Investigator:
- Francesco Tandoi, MD, PhD
-
Bergamo, Italy
- Not yet recruiting
- Ospedale Papa Giovanni XXIII
-
Contact:
- Stefania Camagni, MD
- Phone Number: +39035267111
- Email: stefania.camagni@asst-pg23.it
-
Principal Investigator:
- Stefania Camagni, MD
-
Principal Investigator:
- Domenico Pinelli, MD, PhD
-
Bologna, Italy
- Not yet recruiting
- Policlinico S.Orsola-Malpighi
-
Principal Investigator:
- Matteo Cescon, MD, PhD
-
Contact:
- Matteo Cescon, MD, PhD
- Phone Number: +390512141111
- Email: matteo.cescon@unibo.it
-
Milan, Italy
- Not yet recruiting
- ASST Niguarda Great Metropolitan Hospital
-
Contact:
- Stefano Di Sandro, MD, PhD
- Phone Number: +390264441
- Email: stefano.disandro@unimore.it
-
Principal Investigator:
- Stefano Di Sandro, MD, PhD
-
Milan, Italy
- Not yet recruiting
- Istituto Nazionale dei Tumori
-
Principal Investigator:
- Vincenzo Mazzaferro, MD, PhD
-
Contact:
- Marco Angelo MD, MSc, Bongini
- Phone Number: +390223901
- Email: marco.bongini@istitutotumori.mi.it
-
Sub-Investigator:
- Marco Angelo Bongini, MD, MSc
-
Milan, Italy
- Not yet recruiting
- Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico
-
Contact:
- Daniele Dondossola, MD, PhD
- Phone Number: +390255031
- Email: dondossola.daniele@gmail.com
-
Principal Investigator:
- Daniele Dondossola, MD, PhD
-
Pisa, Italy
- Not yet recruiting
- A.O.U. Pisana - Ospedale Cisanello
-
Contact:
- Davide Ghinolfi, MD, PhD
- Phone Number: +39050992111
- Email: d.ghinolfi@ao-pisa.toscana.it
-
Principal Investigator:
- Davide Ghinolfi, MD, PhD
-
Roma, Italy
- Not yet recruiting
- Agostino Gemelli University Policlinic
-
Contact:
- Marco Maria Pascale, MD
- Phone Number: +390630151
- Email: marcomaria.pascale@policlinicogemelli.it
-
Principal Investigator:
- Marco Maria Pascale, MD
-
Principal Investigator:
- Ugo Boggi, MD, PhD
-
Roma, Italy
- Not yet recruiting
- Clinica ospedaliero-universitaria Policlinico Umberto I
-
Contact:
- Fabio Melandro, MD, PhD
- Phone Number: +390649971
- Email: fabio.melandro@uniroma1.it
-
Principal Investigator:
- Fabio Melandro, MD, PhD
-
Principal Investigator:
- Massimo Rossi, MD, PhD
-
Torino, Italy
- Recruiting
- A.O.U. Città della Salute e della Scienza
-
Contact:
- Damiano Patrono, MD, PhD
- Phone Number: +39011693 3111
- Email: damiano.patrono@gmail.com
-
Principal Investigator:
- Damiano Patrono, MD, PhD
-
Verona, Italy
- Not yet recruiting
- A.O.U. Integrata Verona
-
Contact:
- Amedeo Carraro, MD, PhD
- Phone Number: +390458121111
- Email: amedeo.carraro@aovr.veneto.it
-
Principal Investigator:
- Amedeo Carraro, MD, PhD
-
-
-
-
-
Groningen, Netherlands
- Recruiting
- University Medical Center Groningen
-
Principal Investigator:
- Vincent E de Meijer, MD, PhD
-
Contact:
- Sabrina Stimmeder, MD
- Phone Number: +31503612896
- Email: s.stimmeder@umcg.nl
-
Leiden, Netherlands
- Not yet recruiting
- Leiden University Medical Center
-
Contact:
- Ian Alwayn, MD, PhD
- Phone Number: +31715269111
- Email: i.p.j.alwayn@lumc.nl
-
Principal Investigator:
- Ian Alwayn, MD, PhD
-
-
-
-
-
Bucharest, Romania
- Not yet recruiting
- Institutul Clinic Fundeni
-
Contact:
- Florin Botea, MD, PhD
- Phone Number: +40212750500
- Email: florinbotea@gmail.com
-
Principal Investigator:
- Florin Botea, MD, PhD
-
-
-
-
-
Barakaldo, Spain
- Not yet recruiting
- Cruces University Hospital
-
Contact:
- Mikel Gastaca, MD, PhD
- Phone Number: +34946006000
- Email: mikel.gastacamateo@osakidetza.eus
-
Principal Investigator:
- Mikel Gastaca, MD, PhD
-
Barcelona, Spain
- Not yet recruiting
- Hospital Clínic de Barcelona
-
Contact:
- Yiliam Fundora Suárez, MD, PhD
- Phone Number: +34932275400
- Email: FUNDORA@clinic.cat
-
Principal Investigator:
- Yiliam Fundora Suárez, MD, PhD
-
Granada, Spain
- Not yet recruiting
- Hospital Universitario Virgen de las Nieves
-
Contact:
- Alejandro J. Pérez Alonso, MD, PhD
- Phone Number: +34958020000
- Email: alpeal@ugr.es
-
Principal Investigator:
- Alejandro J. Pérez Alonso, MD, PhD
-
Madrid, Spain
- Not yet recruiting
- Hospital General Universitario Gregorio Marañón
-
Contact:
- María Magdalena Salcedo Plaza, MD, PhD
- Phone Number: +34915868000
- Email: msalce01@ucm.es
-
Principal Investigator:
- María Magdalena Salcedo Plaza, MD, PhD
-
Seville, Spain
- Not yet recruiting
- Hospital Universitario Virgen del Rocío
-
Contact:
- Sheila Pereira Arenas
- Phone Number: +34955012000
- Email: spereira-ibis@us.es
-
Principal Investigator:
- Miguel Angel Gómez Bravo, MD, PhD
-
Valladolid, Spain
- Not yet recruiting
- Río Hortega University Hospital
-
Contact:
- Andrea González De Godos, MD
- Phone Number: +34983420400
- Email: agonzalezdeg@saludcastillayleon.es
-
Principal Investigator:
- Andrea González De Godos, MD
-
-
-
-
-
Stockholm, Sweden
- Not yet recruiting
- Karolinska Institutet
-
Contact:
- Gabriel Oniscu, MD, PhD
- Phone Number: +46852480000
- Email: gabriel.oniscu@ki.se
-
Principal Investigator:
- Gabriel Oniscu, MD, PhD
-
-
-
-
-
Bern, Switzerland
- Not yet recruiting
- Bern University Hospital
-
Principal Investigator:
- Philipp Dutkowski, MD, PhD
-
Contact:
- Philipp Dutkowski, MD, PhD
- Phone Number: +41316322111
- Email: philipp.dutkowski@insel.ch
-
Geneva, Switzerland
- Not yet recruiting
- Hôpitaux Universitaires de Genève
-
Contact:
- Philippe Compagnon, MD, PhD
- Phone Number: +41223723311
- Email: philippe.compagnon@hug.ch
-
Principal Investigator:
- Philippe Compagnon, MD, PhD
-
-
-
-
-
Leeds, United Kingdom
- Not yet recruiting
- Leeds Teaching Hospitals NHS Trust
-
Contact:
- Dhakshina Vijayanand, MD, PhD
- Phone Number: +441132433144
- Email: dhakshina.vijayanand@nhs.net
-
Principal Investigator:
- Dhakshina Vijayanand, MD, PhD
-
London, United Kingdom
- Not yet recruiting
- Royal Free London NHS Foundation Trust
-
Contact:
- David Nasralla, MD, PhD
- Phone Number: +442077940500
- Email: david.nasralla@nhs.net
-
Principal Investigator:
- David Nasralla, MD, PhD
-
London, United Kingdom
- Not yet recruiting
- King's College Hospital NHS Foundation Trust
-
Contact:
- Miriam Cortes Cerisuelo, MD, PhD
- Phone Number: +442032999000
- Email: m.cortescerisuelo@nhs.net
-
Principal Investigator:
- Miriam Cortes Cerisuelo, MD, PhD
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
All postmortal livers accepted (transplanted and not-transplanted after machine perfusion) upon organ offer between 01.01.2021 and 31.12.2025 for patients >18 years at the time of liver transplantation.
Description
Inclusion Criteria:
-
All postmortal livers accepted (transplanted and not-transplanted after machine perfusion) upon organ offer for patients >18 years at the time of liver transplantation.
-
All donor types (DBD, DCD)
-
Preservation either with static cold storage alone or combined with machine perfusion (MP).
-
Donor livers underwent MP as part of routine clinical practice and the choice of perfusion protocol was made according to institutional standard practice.
-
Eligible MP protocols are:
- end-ischemic single- or dual hypothermic oxygenated MP [e(D)HOPE],
- end-ischemic (back-to-base) normothermic MP [eNMP],
- continuous (device-to-donor) normothermic MP [cNMP],
- e(D)HOPE followed by controlled oxygenated rewarming and normothermic MP [e(D)HOPE-COR-NMP)],
- e(D)HOPE followed by normothermic MP [e(D)HOPE-NMP], or
- Normothermic regional perfusion followed by SCS or an ex situ MP protocol.
-
A minimum follow-up of 12 months after liver transplantation is required.
Exclusion Criteria:
- Livers that were allocated to a MP protocol as part of a prospective randomized or interventional clinical trial comparing different preservation techniques or any other invention.
- Living donor liver transplantation
Study Plan
How is the study designed?
Design Details
- Observational Models: COHORT
- Time Perspectives: RETROSPECTIVE
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Death-censored graft survival
Time Frame: Actuarial survival 1-5 year post-transplantation
|
Defined as the time from liver transplantation until re-transplantation or death due to graft failure (analyzed using time-to-event methods). |
Actuarial survival 1-5 year post-transplantation
|
|
Overall patient survival
Time Frame: Actuarial survival 1-5 year post-transplantation
|
Defined as time from liver transplantation until re-transplantation or all-cause death (analyzed using time-to-event methods). |
Actuarial survival 1-5 year post-transplantation
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Incidence of acute rejection
Time Frame: within 1 year post-transplantation, up to 5 years post-transplantation
|
within 1 year post-transplantation, up to 5 years post-transplantation
|
|
|
Incidence of chronic rejection
Time Frame: within 1 year post-transplantation, up to 5 years post-transplantation
|
within 1 year post-transplantation, up to 5 years post-transplantation
|
|
|
Overall graft survival
Time Frame: Actuarial survival 1-5 year post-transplantation
|
Defined as time from liver transplantation until re-transplantation or all-cause death (analyzed using time-to-event methods) |
Actuarial survival 1-5 year post-transplantation
|
|
Incidence of major liver-related complications
Time Frame: within the transplant-related admission, and 1 year post-transplantation
|
Incidence of at least one biliary or vascular complication graded as Clavien-Dindo IIIb or higher, following the grading recommendations published: de Goeij FHC, Wehrle CJ, Abbassi F, et al. Mastering the narrative: Precision reporting of risk and outcomes in liver transplantation. J Hepatol. 2025;82(4):729-743. doi:10.1016/j.jhep.2024.11.013. Additionally, scoring accoring the Comprehensive Complication Index. |
within the transplant-related admission, and 1 year post-transplantation
|
|
Incidence of graft loss due to complications
Time Frame: within 1 year post-transplantation, up to 5 years post-transplantation
|
Graft loss as a result of complications assessed separately for biliary complications, vascular complications, and rejection. |
within 1 year post-transplantation, up to 5 years post-transplantation
|
|
Total number of clinically significant biliary complications
Time Frame: within 1 year post-transplantation, up to 5 years post-transplantation
|
Total number of any biliary complications requiring interventions (Clavien-Dindo grade IIIa or higher). |
within 1 year post-transplantation, up to 5 years post-transplantation
|
|
Incidence of biliary complications
Time Frame: within 1 year post-transplantation, up to 5 years post-transplantation
|
Biliary complications include:
|
within 1 year post-transplantation, up to 5 years post-transplantation
|
|
Incidence of vascular complications
Time Frame: within 1 year post-transplantation, up to 5 years post-transplantation
|
Vascular complications include:
|
within 1 year post-transplantation, up to 5 years post-transplantation
|
|
Incidence of re-transplantation
Time Frame: within 1 year post-transplantation, up to 5 years post-transplantation
|
Re-transplantation for any cause. |
within 1 year post-transplantation, up to 5 years post-transplantation
|
|
Incidence of recurrence of primary disease
Time Frame: within 1 year post-transplantation, up to 5 years post-transplantation
|
Histologically or radiologically confirmed recurrence, including recurrence of malignancies |
within 1 year post-transplantation, up to 5 years post-transplantation
|
|
Incidence of kidney injury
Time Frame: within 1 year post-transplantation, up to 5 years post-transplantation
|
Kidney injury includes:
|
within 1 year post-transplantation, up to 5 years post-transplantation
|
|
Incidence of primary non-function
Time Frame: up to 1 week post-transplantation
|
Liver graft failure within the first 7 days of transplantation with patent liver vessels leading to re-transplantation or patient death |
up to 1 week post-transplantation
|
|
Patient-centered outcomes (measure of recovery and healthcare utilization)
Time Frame: within 1 year post-transplantation
|
Length of intensive care unit stay and length of initial hospital stay (starting at day of transplantation until day of discharge, measured in days) |
within 1 year post-transplantation
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Vincent E de Meijer, MD, PhD, University Medical Center Groningen
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- UMCG_REFRAME-MP
- METc 2026/180 (Registry Identifier: UMCG METc number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.